Advertise on podcast: SCRS Talks

Site engagement often shows up only after a study is already in trouble. In this episode of SCRS Talks, Jimmy Bechtel sits down with Julie Wilhjelm, Senior Director of Site Strategy and Engagement at Novotech, to talk about why it should be built into how studies are planned and run from day one. They cover what separates real engagement from checkbox outreach, how early feedback during feasibility and protocol design can head off costly amendments, and why trust and responsiveness give CROs a real edge with the sites they work with. Julie also gets honest about the revolving door of site contacts, what it costs everyone, and why continuity is so hard to solve at scale. If you work with sites, or you are one, this one is worth a listen.

Lauren Stockwell sits down with Jennifer Larkin, VP of Business Development at M3 Wake Research, to break down what a modern site BD function actually looks like day to day. Jennifer walks through how data intelligence and AI platforms have reshaped feasibility and pipeline management, why relationships alone aren't predictive of future business, and the tiering framework she used to re-rank client accounts based on pipeline fit rather than tenure. The conversation also covers what turns a sponsor-site relationship from transactional to genuinely partnered, why sites should be willing to say no, and the specific metrics, from proposal-to-award conversion to time from award to first patient screened, that reveal whether a BD strategy is actually working.

Jimmy Bechtel sits down with Mike Hutton of Almac Clinical Technologies to talk about where site burden really starts, and what sponsors can do earlier in study design to reduce it. They dig into the difference between protocol complexity and operational complexity, why fragmented systems and workflows quietly pile friction onto site staff, and what a more connected, site-first approach to trial design actually looks like. Mike also shares the one question he wishes more sponsors would ask sites before finalizing a protocol.

Jimmy Bechtel sits down with Megan Richards, Director of Sponsor Operations at CRIO, to talk about how research sites can get more strategic with their data. Megan walks through where to start when identifying the right KPIs, how to build dashboards that actually get used (and the four common pitfalls to avoid), and how benchmarking against industry standards helps sites spot both wins and opportunities for improvement. The conversation wraps with practical advice on turning operational data into a compelling story for sponsors and CROs, strengthening relationships, and winning future study awards.

Jimmy Bechtel talks with Catherine Gregor, Chief Clinical Trial Officer at Florence Healthcare, about Operation Trialblazer and what it means for sites and sponsors. Drawing on her experience running sites (including at Vanderbilt-Ingram Cancer Center) and now working in trial technology, Catherine unpacks why regulatory ambiguity holds both sides back, how CRAs lose major visit time to admin work instead of clinical review, and why data still moves so inefficiently between sites and sponsors. The conversation touches on AI's potential to ease that burden, what rising eTMF pass rates really signal, and what it will take for sites to move faster without losing critical context.

Lauren Stockwell sits down with Rick Greenfield, Founder and Chief Strategy Officer of RealTime eClinical Solutions, to talk about three awards making their debut at the 2026 Global Site Solutions Summit Eagle Awards Gala. Rick and Lauren break down what each award is looking for, from the best exhibit booth in the hall to the person who best embodies the spirit of the summit itself. The bulk of the conversation centers on the Bright Idea Award, which is open to anyone across sites, sponsors, CROs, and vendors who has a solution worth sharing with the industry. Rick also makes a case for why participant experience is one of the biggest areas ripe for a fresh idea. If you are heading to Global this October and have been sitting on an idea or just want to know what to look forward to at the gala, this is a quick and worthwhile listen.

In this episode of SCRS Talks, Lauren Stockwell sits down with Dave Damrau, VP of Global Clinical Operations for the Americas, and Amy Cramer, Global Head of eSource Data Acquisition, both from Johnson & Johnson Innovative Medicine, to unpack J&J's EHR to Sponsor initiative. They discuss why duplicative data entry remains one of the biggest burdens on site staff, what the data shows about the time and error costs of manual transcription, and how eSource solutions are already improving data accuracy. Dave and Amy walk through why oncology became the starting point for this work, what site-driven collaboration has meant for adoption, and what's next as J&J expands EHR to Sponsor into additional therapeutic areas in 2027. Tune in to hear how this initiative aims to reduce friction for sites while creating a more efficient, connected model for clinical research. Join Dave and Amy for the J&J SCRS Summit EHR Action Panel on October 18th from 9:00 to 10:00 AM.

What happens to unused medical supplies when a clinical trial ends? For years the answer was simple: destroy them. Josh Kravitz (MedSurplus Alliance) and Greg Folz (Kits4Life) join Jimmy Bechtel to tell the story of how a stack of boxes, a looming Site Tank deadline, and a crisis in the Congo turned into a program that has now impacted over 6 million lives worldwide. Greg walks through the moment his research staff refused to keep destroying usable supplies, and how that frustration became an idea that won on stage and grew into an industry wide movement. Josh breaks down how trusted partnerships and strict chain of custody get donated supplies from a research site to a clinic or classroom halfway around the world. It's a conversation about waste, generosity, and what's possible when sites push their sponsors to think differently about what happens after a trial ends.

Jimmy Bechtel sits down with Dr. Tia Warrick, CEO of Lesous Consulting, to talk about what actually drives clinical trial failures and what the industry can do about it. With nearly a decade of experience spanning coordinator to CEO, Dr. Warrick brings a ground-level perspective to a problem that costs the industry billions. The conversation covers why so many trials struggle before enrollment even begins, the difference between foundational certifications and true skills-based competency, and what it means that roughly a third of clinical trial failures trace back to workforce gaps we actually have the power to fix. Dr. Warrick also shares her take on where AI fits in, and why it is a useful tool but not a replacement for people who truly know their roles. If your team is thinking about how to build a more resilient, capable workforce and set trials up for success from day one, this episode is worth your time.

In this episode, Jimmy sits down with Brian Burkhardt of the Oliver Patch Project and Andy Shepherd of Project Outrun to talk about the Patchwork Collective, a growing coalition of pediatric oncology advocacy organizations working to bridge the gap between families battling childhood cancer and the clinical trial world. From a "Pharma at the Table" activation at SCOPE to the upcoming Patches & Pairs launch at Give Kids The World, Brian and Andy share how relationship-building and education are the keys to advancing pediatric representation in clinical research.

Jimmy Bechtel sits down with Kimberly Staeck, Head of Global Site Partnerships and Trial Enablement Solutions at Syneos Health, to dig into what it really means to treat sites as partners rather than execution engines. Kimberly brings two decades of operational and partnership experience to a conversation that gets honest about where the industry falls short. They cover why sites have learned to tell the difference between being heard and actually listened to, what closing the feedback loop looks like in practice, and why early site involvement in protocol development is a risk mitigation strategy, not a delay. Kimberly also makes a case for shifting away from activity-based metrics and toward shared outcomes that reflect the real health of a partnership. The throughline is simple: when sites feel valued and supported, patients get better care, staff stay in the field longer, and trials perform. If your organization is serious about moving from transactional to transformational site relationships, this one is worth your time.

Jimmy Bechtel sits down with Brooklyn Montgomery, Business Development Director at Deep Intelligent Pharma (DIP), to explore how agentic AI is reshaping the way clinical research sites operate. Brooklyn breaks down where AI delivers real value for physician-led research, what meaningful adoption actually looks like at the site level, and the three questions every site should answer before spending a dollar on AI tools. The conversation also covers how mentorship and technology work together to close the gap between academic research and clinical execution, and where sites are headed as they move from execution partners to upstream contributors in trial design. Disclaimer: The content of this article reflects interview perspectives and is intended for general informational purposes only. It does not constitute any commitment, representation, or guarantee regarding the performance or outcomes of any product or service. Actual results may vary depending on factors including, but not limited to, study design, data quality, regulatory requirements, and implementation conditions.

Kathy Cox and Ryan Johnsen of Interspond discuss how their platform CROWN is reshaping the study feasibility process for clinical research sites. Rather than sites waiting to be contacted, CROWN puts the power in their hands with a web-based marketplace where they can browse opportunities, manage their profile, and respond to time-sensitive requests all in one place. The result is a smarter, less disruptive feasibility experience built with sites at the center.

In this episode of SCRS Talks, Jimmy Bechtel sits down with Sean Stanton, Founder and CEO of K2 Medical Research, and Christian Burns, Founder and President of Populus Health, to explore how their two organizations are working together to advance CNS drug development. With decades of combined experience across psychiatry, neurology, and neurodegeneration, Sean and Christian discuss what makes CNS trials uniquely challenging, what it takes to earn and maintain trust with sponsors and CROs, and why communication is just as critical as performance metrics. They also share their outlook on the future of the space, from biomarkers and precision health to the growing potential of psychedelics across therapeutic areas, and why CNS research feels less like a job and more like a mission.

In this episode of SCRS Talks, Jimmy Bechtel sits down with Donna Cryer, Chief Patient Officer at Cryer Health and active FDA patient advocate, to explore the critical difference between patient inclusion and patient leadership in drug development. Drawing on her own lifelong experience as a patient, Donna makes the case for why having patients in real positions of authority is not just a values statement but a strategic necessity, especially as AI becomes more embedded in every stage of the research process. From AI governance and model training to the risks of replacing human experience with simulated data, this conversation challenges the industry to stop treating patients as an afterthought and start building their perspectives into the foundation of how research gets done.